Popular diabetes drugs may ease dry eye, study suggests
NCT ID NCT07605572
First seen May 31, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This study is looking at whether GLP-1 receptor agonists—drugs used for type 2 diabetes and obesity—can also improve dry eye disease. Researchers will measure changes in tear stability and eye surface health in 100 patients who have not taken these drugs before. The goal is to understand if these medications have an added benefit for the eyes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
2nd Department of Internal Medicine, Research Institute and Diabetes Center, National and Kapodistrian University of Athens, Athens, GRC.
RECRUITINGAthens, 12462, Greece
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GLP-1 receptor agonists (a class of diabetes and obesity drugs)
What this could lead to
If this study shows a benefit, it could point toward a new way to treat dry eye in people with diabetes and obesity.
What could go wrong
This is an early observational study, not a controlled trial. It may find no effect, and results may not apply to everyone with dry eye.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.